Fig. 2From: Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s diseasePanel a shows the difference in mean amyloid burden and 95 % confidence intervals for changes from baseline at 4 weeks between bexarotene and placebo groups. Panel b shows mean group changes and 95 % confidence intervals at 4 weeks. P-values reflect the comparisons of mean change between groupsBack to article page